# US 12,599,604 B2 · Application of JAK inhibitor in kidney disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,599,604 B2
- Document ID: US12599604B2
- Status: Granted
- Kind: B2
- Application number: 18/266,345
- Filed: 2021-12-10
- Published: 2024-02-15
- Granted: 2026-04-14
- Earliest claimed: 2020-12-11
- Assignees: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Applicants: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Inventors: Cheng Liao; Lu Su; Kan Lin; Jingyang Zhang
- Web page: https://patentgrep.com/patent/US12599604B2

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is an application of a JAK inhibitor in kidney disease. Specifically, provided is a use of a JAK inhibitor in the preparation of a drug for treating or preventing kidney disease.

## Claims

### Claim 1

A method for treating or preventing kidney disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a JAK inhibitor, wherein the kidney disease is selected from acute kidney disease (AKD) or acute kidney injury (AKI), wherein the JAK inhibitor is (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the pharmaceutically acceptable salt is selected from bisulfate, sulfate, methanesulfonate, maleate, tartrate, succinate, acetate, difluoroacetate, fumarate, citrate, a salt of citric acid, malate, hydrochloride, sulfate, and phosphate.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the kidney disease is selected from acute glomerulonephritis, acute interstitial nephritis, idiopathic acute tubulointerstitial nephritis, acute renal insufficiency, drug-induced kidney injury or surgery-related kidney injury.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said kidney disease is selected from a patient with acute kidney injury (AKI) below stage 3 or a patient with acute kidney disease (AKD) below stage 3.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the JAK inhibitor is administered in a human subject at a dosage of 0.5-20 mg.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the JAK inhibitor is administered by oral administration or intravenous injection.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the JAK inhibitor is administered with a frequency of once per day, twice per day or three times per day.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the JAK inhibitor is administered in a human subject at a dosage of 1-5 mg.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the JAK inhibitor is administered in a human subject at a dosage of 1 mg, 2 mg or 4 mg.